In malignant gliomas, the median ratio of FABP5/CRABP2 mRNA expression of 3.6 in short-term survivors (≤6 months) was significantly higher than that of long-term survivors (≥36 months) of 1.4, indicating that the FABP5/CRABP2 ratio can determine the direction of cell differentiation [18]. This evidence concerns the gene CRABP2 and malignant glioma.